Zuckerberg San Francisco General
Welcome,         Profile    Billing    Logout  
 29 Trials 
60 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Deeks, Steven G
PREVAIL-LC, NCT06161688: Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

Recruiting
2
40
US
Ensitrelvir, ensitrelvir fumaric acid, Placebo
Timothy Henrich, Shionogi Inc.
Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19
03/25
12/25
NCT03684655: Imaging Immune Activation in HIV by PET-MR

Recruiting
2
30
US
[18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D-arabinofuranosylguanine), VisAcT
CellSight Technologies, Inc., National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
HIV Infections
10/25
11/25
outSMART-LC, NCT05877508: Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Active, not recruiting
2
30
US
AER002, Placebo
Michael Peluso, MD, Aerium Therapeutics, Patient-Led Research Collaborative, PolyBio Research Foundation
Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19
07/25
07/25
CLEAR HIV, NCT05488431: Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial ( Trial)

Recruiting
2
121
US
Bempedoic acid, BA, Placebo
Priscilla Hsue, MD, University of California, Los Angeles, Massachusetts General Hospital
Dyslipidemias, Cardiovascular Diseases, HIV Infections, Atherosclerosis
03/28
03/28
NCT04648046: CAR-T Cells for HIV Infection

Recruiting
1/2
18
US
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Steven Deeks, Caring Cross
HIV Infections
12/27
12/28
NCT03174977: Pharmacokinetics Distribution of Raltegravir by PET/MR

Recruiting
1
10
US
18F-Raltegravir
University of California, San Francisco, Merck Sharp & Dohme LLC
HIV-1-infection
11/24
01/25
SCOPE-ATI, NCT04359186: SCOPE Analytic Treatment Interruption Protocol

Recruiting
N/A
40
US
Treatment Interruption Arm
University of California, San Francisco, Chan Zuckerberg Biohub
HIV/AIDS
06/25
06/26
NCT05172024: Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

Active, not recruiting
N/A
15178
US
NYU Langone Health, National Heart, Lung, and Blood Institute (NHLBI)
SARS-CoV2 Infection
04/25
05/25
LIINC, NCT04362150: Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Recruiting
N/A
800
US
University of California, San Francisco
COVID
12/25
12/25
NCT01336855: Collection of Blood for Multiple Collaborative Studies

Recruiting
N/A
2000
US
University of California, San Francisco
HIV
01/30
01/30
NCT01202305: The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

Recruiting
N/A
50
US
Lymph node biopsy
University of California, San Francisco, National Institutes of Health (NIH)
HIV
04/30
04/30
NCT00187512: SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Recruiting
N/A
2500
US
University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/32
12/33
NCT01161199: The Use of Leukapheresis to Support HIV Pathogenesis Studies

Recruiting
N/A
100
US
Leukapheresis
University of California, San Francisco
HIV
07/33
07/33
Abedi, Mehrdad
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

Terminated
3
130
US
AB-205, E-CEL cells, Placebo
Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM)
Hodgkin Lymphoma, Non Hodgkin Lymphoma
12/23
01/24
GRASP, NCT05353647: A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (, BMT CTN 2001)

Recruiting
2
25
US
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
David Williams, National Heart, Lung, and Blood Institute (NHLBI), California Institute for Regenerative Medicine (CIRM), bluebird bio, Blood and Marrow Transplant Clinical Trials Network
Sickle Cell Disease
05/26
05/26
EBVision, NCT04554914 / 2020-000177-25: A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Hourglass Jan 2023 - Dec 2023 : From P2 trial for Epstein-Barr virus-associated sarcoma
Recruiting
2
190
Europe, US
Tabelecleucel, tab-cel®, ATA129, EBV-CTLs
Atara Biotherapeutics
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD), EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications, EBV+ Sarcomas, Leiomyosarcoma
06/27
05/29
NCT02797470: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

Active, not recruiting
1/2
11
US
Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Laboratory Biomarker Analysis, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells, Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive HPCs, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation
AIDS Malignancy Consortium, National Cancer Institute (NCI), California Institute for Regenerative Medicine (CIRM)
HIV Infection, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Plasmablastic Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Follicular Lymphoma, Stage III Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
05/21
06/25
Starlight-1, NCT06343311: T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Recruiting
1/2
21
US
EB103
Estrella Biopharma, Inc., Eureka Therapeutics Inc.
B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell, Non-Hodgkin Lymphoma, Non-Hodgkin's Lymphoma, Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin's, Adult, Lymphoma, Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Lymphoma, Non-Hodgkin, HIV Associated Lymphoma, CNS Lymphoma, High-grade B-cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
12/26
12/27
FELIX, NCT04404660: A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Active, not recruiting
1/2
153
NA
AUTO1, Obecabtagene autoleucel (obe-cel)
Autolus Limited
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
05/25
05/25
NCT04648046: CAR-T Cells for HIV Infection

Recruiting
1/2
18
US
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Steven Deeks, Caring Cross
HIV Infections
12/27
12/28
LIMBER-TREG108, NCT05423691: Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Recruiting
1
24
US
CK0804
Cellenkos, Inc.
Myelofibrosis
04/24
04/24
BMSCRP1, NCT04925687: Phase 1 Study of Intravitreal Autologous CD34+ Stem Cell Therapy for Retinitis Pigmentosa

Completed
1
4
US
Intravitreal autologous CD34+ cells
University of California, Davis, Cures Within Reach, The Retina Society
Retinitis Pigmentosa
11/23
11/23
OGFT001-001, NCT03802695: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Recruiting
1
186
US
OrcaGraft (Orca-Q)
Orca Biosystems, Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia
04/26
04/28
NCT05052528: Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
1
36
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine Phosphate, 2-F-ara-AMP, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, SH T 586, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
Mehrdad Abedi, MD, National Cancer Institute (NCI)
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
05/25
12/25
NEXICART-2, NCT06097832: Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis

Recruiting
1
40
US
NXC-201 CAR-T, HBI0101 CAR-T
Nexcella Inc., Immix Biopharma, Inc.
Light Chain (AL) Amyloidosis
12/26
01/39
NCT04422912: A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Recruiting
1
55
US
DSG3-CAART or CABA-201
Cabaletta Bio
Pemphigus Vulgaris
01/29
01/29
Weiser, Sheri
CHEFS-DM, NCT04959487: Changing Health Through Food Support for Diabetes

Active, not recruiting
N/A
281
US
Food support, Nutritional Counseling and education
University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Project Open Hand
Type 2 Diabetes, Food Insecurity
01/25
08/25
Wu, Alan
NCT04191057: Determining Normal Range for Free Light Chains in Serum Among Twins

Completed
N/A
32
US
Free light chains
University of California, San Francisco
Multiple Myeloma
01/24
01/24
Blarigan, Erin L Van
OATS II, NCT05746195: Optimization of Adaptive Text Messages for Cancer Survivors

Recruiting
N/A
60
US
Dietary intervention via Text Messaging, Survey Administration, Nutrition Education
University of California, San Francisco, National Cancer Institute (NCI)
Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
11/24
11/24
NCT06602999: Addressing the Nutritional Needs of Cancer Survivors With Nutrition Insecurity

Not yet recruiting
N/A
30
US
Nutritional Intervention, Instacart Voucher, Telephone-Based Intervention
University of California, San Francisco, National Cancer Institute (NCI), Stanford University
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
05/27
05/27
TTBF, NCT05056077: Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

Recruiting
N/A
1000
US
Counseling, Counseling Intervention, Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Health Education, Health Coaching, Health Promotion and Education - Direct Text Messaging, Text Messaging, Health Promotion and Education - Digital health tool kit, Educational, Digital health tool kit, Questionnaires, Quality of Life Questionnaires, Optional Blood Specimen, Optional Stool Specimens
University of California, San Francisco, National Cancer Institute (NCI), University of California, Davis, Robert H. Lurie Cancer Center, Dana-Farber Cancer Institute
Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Rectal Cancer, Prostate Cancer, Renal Cell Carcinoma, Kidney Cancer
12/27
12/27
Prostate 8-II, NCT03999151: Diet and Exercise Interventions Among Men With Prostate Cancer

Active, not recruiting
N/A
204
US
Exercise and Diet
University of California, San Francisco, National Cancer Institute (NCI)
Prostate Cancer
08/28
08/28
Schueller, Stephen M
NCT05687162: SSIs for Mental Health and Loneliness

Completed
N/A
4370
US
Overcoming Loneliness three-week intervention, Overcoming Loneliness single-session intervention, Single-session "Sharing Feelings" program, The Blu Surfer program: a popular online content-based intervention for psychological distress, The Action Brings Change (ABC) Program (TEAM Lab version), Online help-seeking as usual, The Lonely Blu Surfer program: a popular online content-based intervention for loneliness, Overcoming loneliness SSI 8-minute version
University of California, Irvine, Jacobs Foundation
Loneliness, Mental Health Issue, Distress, Emotional, Depression, Anxiety, Stress
09/23
09/23
SUPERA, NCT05746767: Supporting Peer Interactions to Expand Access to Digital Cognitive Behavioral Therapy for Spanish-speaking Patients

Enrolling by invitation
N/A
426
US
Supported dCBT, Unsupported dCBT
University of California, Irvine, National Institute of Mental Health (NIMH), University of California, Berkeley, University of California, San Francisco
Depression, Anxiety
03/27
03/27
Dixit, Niharika
NCT04939090: Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Recruiting
3
360
US
Olanzapine, Megestrol Acetate, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
05/26
12/26
NCT06058377: Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Recruiting
3
3680
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B 518, B-518, B518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR 138719, WR- 138719, WR-138719, WR138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI 4736, MEDI-4736, MEDI4736, Genetic Testing, Genetic Analysis, Genetic Examination, Genetic Test, Mammography, MG, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment
National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Localized Breast Carcinoma
05/26
05/26
NCT05812807: Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Recruiting
3
1295
US
Pembrolizumab, Keytruda, Patient Observation, Active surveillance, watchful waiting, observation, Biopsy, Biospecimen Collection, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Early Stage Triple-Negative Breast Carcinoma
05/33
05/33
NCT04266249: CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

Recruiting
2
2156
US
Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Lumpectomy, Lumpectomy of Breast, Partial Mastectomy, Mastectomy, Mammectomy, Nab-paclitaxel, ABI 007, ABI-007, Abraxane, Albumin-bound Paclitaxel, Albumin-Stabilized Nanoparticle Paclitaxel, Nanoparticle Albumin-bound Paclitaxel, Nanoparticle Paclitaxel, Paclitaxel Albumin, paclitaxel albumin-stabilized nanoparticle formulation, protein-bound paclitaxel, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pertuzumab, 2C4, 2C4 Antibody, MoAb 2C4, Monoclonal Antibody 2C4, Omnitarg, Perjeta, rhuMAb2C4, RO4368451, Radiation Therapy, Cancer Radiotherapy, Irradiate, irradiated, irradiation, RADIATION, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Trastuzumab, ABP 980, ALT02, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, Herzuma, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, Ogivri, Ontruzant, PF-05280014, rhuMAb HER2, RO0452317, SB3, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar ALT02, trastuzumab biosimilar EG12014, Trastuzumab Biosimilar HLX02, Trastuzumab Biosimilar PF-05280014, Trastuzumab Biosimilar SB3, Trastuzumab-dkst, Trastuzumab-dttb, Trastuzumab-pkrb, Trastuzumab-QYYP, Trazimera, Trastuzumab Emtansine, Ado Trastuzumab Emtansine, ADO-Trastuzumab Emtansine, Kadcyla, PRO132365, RO5304020, T-DM1, Trastuzumab-DM1, Trastuzumab-MCC-DM1, Trastuzumab-MCC-DM1 Antibody-Drug Conjugate, Trastuzumab-MCC-DM1 Immunoconjugate
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
10/26
12/38
NCT06633926: Integrative Approaches for Cancer Survivorship (IACS3)

Not yet recruiting
N/A
104
US
Nutrition Education, Lifestyle Counseling, Yoga, Yoga therapy, Marma therapy, Marma therapeutic touch therapy, Therapeutic touch therapy, Educational Intervention, Education for Intervention, Quality of Life Questionnaire Administration, Quality of Life Survey
University of California, San Francisco, National Center for Complementary and Integrative Health (NCCIH)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
12/26
06/27
NCT05297734: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Recruiting
N/A
2996
US
Receive technology-based supportive cancer care, Technology-based SCC approach, Receive redesigned team-based supportive cancer care, Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach
Stanford University, Patient-Centered Outcomes Research Institute
End of Life, Cancer
01/28
02/28
Hoh, Rebecca
NCT04648046: CAR-T Cells for HIV Infection

Recruiting
1/2
18
US
Cyclophosphamide, LVgp120duoCAR-T cells, low dose, LVgp120duoCAR-T cells, high dose, Analytic Treatment Interruption
Steven Deeks, Caring Cross
HIV Infections
12/27
12/28
SCOPE-ATI, NCT04359186: SCOPE Analytic Treatment Interruption Protocol

Recruiting
N/A
40
US
Treatment Interruption Arm
University of California, San Francisco, Chan Zuckerberg Biohub
HIV/AIDS
06/25
06/26
LIINC, NCT04362150: Long-term Impact of Infection With Novel Coronavirus (COVID-19)

Recruiting
N/A
800
US
University of California, San Francisco
COVID
12/25
12/25
NCT00187512: SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

Recruiting
N/A
2500
US
University of California, San Francisco, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/32
12/33
Beatty, Alexis
NCT06055803: Heart Health After Cancer Treatment (HEART-ACT)

Recruiting
N/A
50
US
Intake Session, Individual Sessions, Group Sessions, Graduation, Exercise
University of California, San Francisco
Breast Cancer
12/25
12/25
NCT05933083: MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation

Recruiting
N/A
516
US
In-person cardiac rehabilitation, Telehealth cardiac rehabilitation
University of California, San Francisco, Patient-Centered Outcomes Research Institute, Mayo Clinic, University of Michigan, University of Pittsburgh, Johns Hopkins University
Myocardial Infarction, Heart Failure, Systolic, Heart Valve Diseases, Angina, Stable, Coronary Artery Disease, Heart Transplant
10/26
10/27
Fortuna, Lisa
SUPERA, NCT05746767: Supporting Peer Interactions to Expand Access to Digital Cognitive Behavioral Therapy for Spanish-speaking Patients

Enrolling by invitation
N/A
426
US
Supported dCBT, Unsupported dCBT
University of California, Irvine, National Institute of Mental Health (NIMH), University of California, Berkeley, University of California, San Francisco
Depression, Anxiety
03/27
03/27
Palar, Kartika
NU-DSMP, NCT05067452: Pilot Trial of the Nutrition-Supported Diabetes Education Program

Recruiting
N/A
72
US
Food support, Case-management
University of California, San Francisco, Project Open Hand, Contra Costa Health Services, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 2
05/23
08/23
CHEFS-DM, NCT04959487: Changing Health Through Food Support for Diabetes

Active, not recruiting
N/A
281
US
Food support, Nutritional Counseling and education
University of California, San Francisco, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Project Open Hand
Type 2 Diabetes, Food Insecurity
01/25
08/25
Steiding, Paige
OATS II, NCT05746195: Optimization of Adaptive Text Messages for Cancer Survivors

Recruiting
N/A
60
US
Dietary intervention via Text Messaging, Survey Administration, Nutrition Education
University of California, San Francisco, National Cancer Institute (NCI)
Colon Adenocarcinoma, Colorectal Carcinoma, Rectal Adenocarcinoma
11/24
11/24
TTBF, NCT05056077: Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)

Recruiting
N/A
1000
US
Counseling, Counseling Intervention, Educational Intervention, Education for Intervention, Intervention by Education, Intervention through Education, Intervention, Educational, Health Education, Health Coaching, Health Promotion and Education - Direct Text Messaging, Text Messaging, Health Promotion and Education - Digital health tool kit, Educational, Digital health tool kit, Questionnaires, Quality of Life Questionnaires, Optional Blood Specimen, Optional Stool Specimens
University of California, San Francisco, National Cancer Institute (NCI), University of California, Davis, Robert H. Lurie Cancer Center, Dana-Farber Cancer Institute
Bladder Cancer, Breast Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Rectal Cancer, Prostate Cancer, Renal Cell Carcinoma, Kidney Cancer
12/27
12/27
PanNEN, NCT05746182: Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms

Recruiting
N/A
300
US
Hereditary Cancer Panel, University of California, San Francisco's (UCSF) Expanded Hereditary Cancer Panel, Germline Testing
University of California, San Francisco, University of California Pancreatic Cancer Consortium (UCPCC)
Pancreatic Neuroendocrine Neoplasm
12/25
12/25
Liu, Raymond
NCT05297734: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer

Recruiting
N/A
2996
US
Receive technology-based supportive cancer care, Technology-based SCC approach, Receive redesigned team-based supportive cancer care, Patients Activated in Cancer care through Teams (PACT), Redesigned SCC team-based approach
Stanford University, Patient-Centered Outcomes Research Institute
End of Life, Cancer
01/28
02/28
Zier, Lucas
NCT05206422: DORAYA-HF Early Feasibility Study

Recruiting
N/A
30
US
Doraya catheter
Revamp Medical Inc.
Acute Decompensated Heart Failure
12/24
03/25
Steineman, Katherine
NCT05206422: DORAYA-HF Early Feasibility Study

Recruiting
N/A
30
US
Doraya catheter
Revamp Medical Inc.
Acute Decompensated Heart Failure
12/24
03/25
NCT05677100: Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure

Recruiting
N/A
268
US
Aortix System, Aortix Pump
Procyrion
Heart Failure, Cardiorenal Syndrome, Cardio-Renal Syndrome, ADHF, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure; With Decompensation, Heart Failure, Congestive
07/25
12/25
Leung, Ivan
NCT06055803: Heart Health After Cancer Treatment (HEART-ACT)

Recruiting
N/A
50
US
Intake Session, Individual Sessions, Group Sessions, Graduation, Exercise
University of California, San Francisco
Breast Cancer
12/25
12/25
NCT05663502: Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

Recruiting
N/A
200
US
Biospecimen Collection, Biological Sample Collection
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Anal Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Kaposi Sarcoma, Lymphoma, Malignant Solid Neoplasm, Multicentric Castleman Disease, Plasmablastic Lymphoma, Recurrent Kaposi Sarcoma, Recurrent Lymphoma, Recurrent Plasmablastic Lymphoma, Transplant-Related Kaposi Sarcoma
08/30
08/35
Couey, Paul
NCT04305691: Trial of Ixazomib for Kaposi Sarcoma

Recruiting
2
41
US
Ixazomib Citrate, MLN-9708, MLN9708, Ninlaro, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
AIDS Malignancy Consortium, National Cancer Institute (NCI)
Kaposi Sarcoma, Skin
05/25
05/26
NCT06602999: Addressing the Nutritional Needs of Cancer Survivors With Nutrition Insecurity

Not yet recruiting
N/A
30
US
Nutritional Intervention, Instacart Voucher, Telephone-Based Intervention
University of California, San Francisco, National Cancer Institute (NCI), Stanford University
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
05/27
05/27

Download Options